CURRICULUM VITAE - Ohio State University · Web viewCURRICULUM VITAE PERSONAL DATA: Name:...

5/6/2023 Revision

CURRICULUM VITAE

PERSONAL DATA:

Name: Natarajan Muthusamy (Raj)Address: Division of Hematology

Dept. of Internal MedicineRoom 455E, OSUCCC Bldg410 West 12th Ave.Columbus, OH 43210(614) 292-8135Email: [email protected]

Born: Cameron Highlands, Pahang, Malaysia

EDUCATION:

Graduate Ph.D. Microbiology and Immunology, 1992 University of Kentucky

Professional B.V.Sc. (=D.V.M) Veterinary Medicine, 1982Madras Veterinary College, Tamil Nadu Agricultural University, Chennai, India

PROFESSIONAL APPOINTMENTS:

2014 – present Professor of Medicine, Division of HematologyDept. of Internal Medicine, OSU

2011 – 2014 Associate Professor of Medicine, Division of HematologyDept. of Internal Medicine, OSU

2007 – 2011 Research Associate Professor, Division of Hematology,Dept. of Internal Medicine, OSU

2014 – present Professor (Adj.) Molecular Virology,Immunology and Medical Generitcs, The Ohio State University

2007 – 2014 Associate Professor (Adj) Molecular Virology, Immunology and Medical Genetics, The Ohio State University

2014 – present Professor (Adj.) Veterinary BioSciences, TheOhio State University

2013 – present Training Grants: Member, OSUCCC Leukemia Research Program

2007 – 2014 Associate Professor (Adj) Veterinary InviBioSciences, The Ohio State University

2004 – 2007 Assistant Professor (Visiting), Division of Hematology, Dept .of Internal Medicine, OSU

Natarajan Muthusamy DVM, PhD

2004 – 2007 Research Scientist-The OSU Comprehensive Cancer Center

2002 – 2004 Assistant Professor (Adj.), Department of Pediatrics, The Ohio State University, Columbus, OH.

1997 – 2007 Assistant Professor (Adj) Molecular Virology, Immunology and Medical Genetics, The Ohio State University

1999 –2007 Assistant Professor (Adj), Dept. Veterinary BioSciences,1998 – 2003 Co-Director, OSUCCC Transgenic/ES Cell Shared

Resources1998 – 2004 Member, Molecular Cellular and Developmental Biology

program, The Ohio State University.1998 – 2013 Member, OSUCCC Immunology Program1997 – 2002 Assistant Professor, Department of Pediatrics, The

Ohio State University and Children’s Hospital ResearchFoundation, Columbus, OH

1997 – 2004 Director, Embryonic Stem Cell Core Laboratory, Children's Hospital Research Foundation, Columbus, OH

1995 – 1997 Research Associate (Instructor), Dept. of Medicine, University of Chicago, Chicago, IL

1992 – 1994 Research Associate, University of Chicago1992 Research Associate, Howard Hughes Medical Institute,

University of Michigan, Ann Arbor, MI1986 – 1992 Research Assistant, University of Kentucky, Lexington,

KY1982 – 1985 Laboratory Animal Veterinary Surgeon, Madurai Kamaraj

University, Madurai, India1982 Veterinary Surgeon, Disease Investigation and Eradication

Unit, Salem Dairy Development Corporation, Salem, India

1982 Junior Manager, Hygeia Feeds and Minerals, Madras, India

HONORS AND AWARDS:

1968 Primary School Leaving Certificate of Merit, Malaysia.1975 – 1982 National Merit Scholarship, Ministry of Education1976 Merit Scholarship. Indian Council of Agricultural Research1986 – 1991 Research Assistantship, University of Kentucky1987 Teaching Assistantship, University of Kentucky1991 University of Kentucky, Graduate Student Research Award1998 ‘Free Communication Merit Award’. 10th Int’l. Congress of

Immunology New Delhi, India Nov1-7,19981998 American Association of Immunologists. Travel Award to

the 10th Int’l. Congress of Immunology New Delhi, India Nov1-7

2


2001 American Association of Immunologists. Junior Faculty Certificate of appreciation and Travel Award, FASEB Meeting, Orlando, FL

2001 American Association of Immunologists. Travel Award to the 11th Int’l. Congress of Immunology, Stockholm, Sweden

2001 American Cancer Society, ‘Heroes of Hope’ AwardOctober 20, 2001

2012 Elected Member, Henry Kunkel SocietyMarch, 2012

Research Grants (Current) Current Grants as PI : (Active)

2013 – 2018 NCI-R01- CA165469-01A1 - Role of TCL1 and Par-4 in regulation of chronic lymphocytic leukemia. (PIs: Muthusamy/Bondada and Ranganekar).(Role: MPI) /(PI-OSU subcontract)

2012 – 2017 NIH-R01- CA159296-01A1 (PIs-Muthusamy & Byrd) Novel Immunotherapies for Lymphoid Malignancies (Role: PI)

2002 – 2017 NCI- 5 P01 CA95426-12 Innate immunity: elucidation and modulation for cancer therapy (PPG PI: Michael Caligiuri- Core C- Mouse modeling and Animal Development (Role: PI-Core C)

2011 – 2016 NIH – R01 – CA135332-03 (PIs: Muthusamy & Marcucci)Validation of microRNAs as Therapeutic Targets in Hematological malignancies (Role: PI)

2010 – 2015 LLS 7004-11- Leukemia & Lymphoma Society - Specialized Center Of Research-Experimental Therapeutics in CLL (SCOR PI- John Byrd) Project: 4: Therapeutic Targeting of SHP-1 and PP2A Protein Phosphates in Lymphoid Leukemia (PIs: Muthusamy and Perrotti) (Role: PI- Project 4)

Current Grants as Co-investigator (Active)

2002 – 2017 NCI-5 P01 CA95426-12 (PI: Caligiuri). Innate immunity: elucidation and modulation for cancer therapy. Project 1 (PI-John Byrd): Clinical investigation of the innate immune system. (Role: Co-Investigator)

2015 – 2019 ACS Scholar RSG-14-243-01-LIB – (PI: Yu) CS1 Chimeric Antigen Receptor-Based Immunotherapy for Multiple Myeloma –

3


Aim 1: To optimize CAR NK cells and combine them with other approaches for treatment of MM. Aim 2: To study the mechanisms by which the second generation CAR improves NK cell effector functions. Aim 3: To develop GMP-grade CS1-CAR virus, master cell banks, and clinical-grade CS1-CAR NK-92 cells for use in a future clinical trial in relapsed MM. (Role: Co-Investigator)

Training Grants:

2013 – 2018 System in Integrative Biology T32 Grant(Role: Participating Faculty)

2013 – 2018 Mouse Pathobiology: Models of Human Disease T32 Grant(Role: Participating Faculty)

2013 – 2018 Medical Scientist Training Program T32 Grant(role: Participating Faculty)

Pending Grant Submissions:

2015 - 2020 NCI R01(PAR 13-302) – Phosphatase Activation as Therapeutic Strategy for Chronic Lymphocytic Leukemia.(Role: PI)

2015 - 2020 U54 – CCNE – Ohio Center for Nanotechnology Excellence. Integration of Nano-fluidic Electroporation to identify and characterize leukemic stem cell properties and drug resistance in leukemia(Role: Co-Leader, Project 4)

Research Grants- funded (past):

2009 – 2014 NCI SPORE P50 CA140158-05 - Experimental therapeutics of leukemia – Project 3: Lenalidomide as an Immune Modulating Agent for Chronic Lymphocytic Leukemia. (Role: Co-Investigator)

2012 - 2013 10010859-45024 Boehringer Ingelheim (PI:Marcucci) In vitro evaluation of MAb 33.1 on primary CD33 antibody, alone and in combination with either lenalidomide or decitabine. Muthusamy Co-Investigator

2011 – 2013 NCCN (approved for funding- Declined) (PI: Muthusamy) A Phase I/II study of the gamma-chain receptor cytokine IL-21 + oftaumumab in previously treated chronic lymphocytic leukemia

4


(CLL)/small lymphocytic leukemia (SLL) and B-prolymphocytic leukemia (PLL). (Role: PI)

2008 – 2013 NIH-RO1- CA135243-01 (PI: Lee) Targeted Lipoplexes for oligonucleotide delivery to Acute Myeloid Leukemia (PIs-Robert Lee and Guido Marcucci) Muthusamy-Co-investigator

2007 – 2010 Leukemia & Lymphoma Society- Translational Grant (2008-2011)-Targeting CD37 with Small Modular Immune pharmaceutical TRU16 (PI-John Byrd- Muthusamy-Co-investigator

2005 – 2010 Leukemia & Lymphoma Society - Specialized Center of Research Grant- (SCOR PI-John Byrd)- Mouse Translational Core- (PI- Muthusamy)

2005 – 2010 7080-06 Leukemia & Lymphoma Society SCOR - Experimental therapeutics in CLL. (Project 3, Therapeutic Targeting of Novel Kinases in CLL -PI- John Byrd. Muthusamy Co-investigator

2005 – 2010 7080-06 Leukemia & Lymphoma Society SCOR - Experimental therapeutics in CLL. (Core A- Cytogenetics and Immunophenotyping core- Core PI-Nyla Heerema, Muthusamy-Co-Investigator

2006 – 2007 OSU CCC Experimental therapeutics Program Seed Grant-(PI-Muthusamy/Byrd)

2003 – 2008 NIH/ PA-01-138- NCRR Training Grant for Veterinary students in Animal-oriented, hypothesis based research (Principal Investigator- Michael Larimore) Muthusamy (Co-investigator)

2003 – 2007 NCI-Mayo Clinic Mayo Fund-NIH Subcontract: 5 R01 CA095241-02-OHIO PI: Kay (Subcontract PI: Byrd). B-CLL biology: Impact of combination chemotherapy. Supplement to grant #: Mayo Fnd-NIH Subcontract: R01 CA095241 (Co-I)

2007 – 2007 1-T32 RR07073-NIH Mouse Pathobiology: Models of Human Disease, Thomas Rosol (PI) Muthusamy Co-investigator

2000 – 2005 RO1/NIH Pravin Kaumaya (PI) Muthusamy, N. (Co. PI)2000 – 2001 American Cancer Society, Ohio Division (PI)2000 – 2001 ALS Therapy Foundation (PI)1999 – 2004 P30 CA16058- NIH/National Cancer Institute -Comprehensive cancer center

Transgenic Animals Shared Resource (PI) 1999 – 2001 Ohio Cancer Research Associates Award (PI)1998 – 1999 OSUCCC-CHRI Research award (PI)1998 – 1999 OSUCCC Pediatric Oncology program seed grant (PI)1998 – 1999 OSUCCC-CHRI-Investigator Training in Transgenic and ES cell

technologies (PI)1998 – 1999 American Cancer Society, Institutional Research Grant (PI)1998 – 1999 The Ohio State University Seed Grant (PI)1991 University of Kentucky Graduate Student Research Award (PI)

CLINICAL PROTOCOLS AS LABORATORY PI/Co-I:

5


2010 – present OSU-10020 “A Phase I Study of XmAB®5574 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia”

2010 - present Tru016- OSU- 07154-A Phase 1/2 Study of TRU-016 inPatients with Previously Treated Chronic

Lymphocytic Leukemia2010 - 2011 OSU-09013 A phase I study of GNKG168 administered by

intravenous infusion in patients with relapsed or refractory B-cell Chronic lymphocytic leukemia (B-CLL)

2015 Randomized Phase II trial of ibrutinib vs. ibrutinib and lenalidomide in previously treated patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

TEACHING/TRAINING EXPERIENCE:

2010 – present Teacher (team) IBGP 880.01 (8800.01) Signature Program Translational Science Curriculum-Immunology &

Inflammation2007 – present Co-Director- INT. MED-850.01 (8891.01) Signal

Transduction in the Immune System1998 – Present Teacher (team) MVIMG-701 (7010) Cellular and

Molecular Immunology2005 Director- MMI 814/ Advance topics in Immunology 2002 Moderator- MCDB 800/890 student seminar spring 20022002 Med II Immunology-Division II 2001 Course Co-Director –MMI 833 Methods in Immunology1999 (Course Director) MMI 814/ Transgenic and gene targeted

mouse models in Immunology1999 Teacher (team) Medical Biochemistry 823 Molecular

control mechanisms of cell proliferation1999 Course Co-Organizer –MMI 833 Methods in Immunology 1998 Course Co-Organizer - OSU Transgenic/Embryonic Stem

Cell Workshop1998 Academic Research Elective Course- Research Training for

medical students1998 Teacher (team) MMI 814(Seminar in Medical

Microbiology)1987 Teaching assistant- University of Kentucky. Pathogenic

bacteriology (BIO585)

GRADUATE/PROFESSIONAL EDUCATION AND TRAINING:

Postdoctoral Trainees:

1) Dr. Ramadevi Raghunandhan Ph.D. (1997-2001)

6


2) Dr. Mohamed Bayoumy M.D. Fellow, Pediatric Hematology and Oncology Division (2000-2002)

3) Dr. Aruna Gowda M.D., Fellow, Hematology and Oncology Division (2005- 2008- laboratory Co-Mentor)

4) Dr. Rosa Lapalombella Ph.D- Visiting scholar, Hematology and Oncology Division (2006 - 2011- Co-Mentor)

5) Julie Road Ph.D- PDF, Hematology and Oncology Division (2006- 2007 - Co-Mentor)

6) Dr. Farrukh Awan, M.D., Fellow, Hematology and Oncology Division (2007-2009 – laboratory Co-Mentor)

7) Dr. Li-Yuan Bai, MD. – Visiting scholar, Hematology and Oncology Division (2008-2009) Medical University of China, Taiwan

8) Dr. Brindha Narayanan- Visiting Scholar under Government of India fellowship/Assistant Professor- Tamil Nadu Veterinary University., India (2010)

9) Jason Dubovsky, Ph.D. (2011 – present) - T-32 Fellowship10) Deborah Stephens, DO (2012 – 2014)11) Rajeswaran Mani, DVM, PhD (2009 – present) College of Veterinary

Medicine, The Ohio State University

Graduate Education:

Past Doctoral Students (dissertation advisor and committee chair)

1) Hui-Chen Chen - Graduated in 2003, Dept. Molecular Virology, Immunology and Medical Genetics, Current position: Assistant Professor

2) Ian Fisher- Graduated in 2004, Molecular Cellular and Developmental and Biology (MCDB) Program, The Ohio State University, Current position: Research Scientist

3) Bo Yu- Graduated in 2010, College of Engineering, The Ohio State University, Current position: Private Sector

4) Sarwish Rafiq - Graduate 2012, IBGP Program, The Ohio State University, Current Position: Post-doctoral Fellow

5) Yicheng Mao – Graduated 2012, College of Pharmacy, The Ohio State University, Current Position: Academic Researcher

6) Rajeswaran Mani – Graduated 2014, College of Veterinary Medicine, The Ohio State University, Current Position: Post-Doctoral Researcher

Doctoral Students (dissertation mentorship)

1) Rajeswaran Mani-College of Veterinary Medicine, OSU (Mentor- 2014)

2) Xiaobin Zhao-College of Pharmacy, OSU (Co-mentor 2007)3) Qing Liu- College of Pharmacy, OSU (Co-mentor 2008)

7


4) Georgia Triantafillou – IBGP Program, OSU (Co-mentor 2009)5) Sarwish Rafiq – IBGP Program, OSU (Co-mentor 2009)6) Justin Staubli, IBGP Program, OSU (Co-mentor 2009)7) Bo Yu- College of Engineering, OSU (Co-Advisor 2010)8) Yicheng Mao- College of Pharmacy, OSU (Co-mentor 2009)9) Rebekah Browning-IBGP program, OSU (Co-mentor-2010)10) Emily McWilliams-IBGP Program, OSU (Co-Mentor)11) Priscilla Do-IBGP Program, OSU (Co-Mentor)12) Chi-ling Chiang-IBGP Program, OSU (Co-Mentor)13) Kyle Beckwith, MD/PhD Student, OSU (Co-Mentor)14) Nicholas Denton-IBGP program, OSU (1st year advisor)

National Mentorship Committees

1) The American Society of Hematology, Minority Medical Student Scholar Program (2013 – present)

Masters Student (dissertation advisor and committee chair)

1) Frank Frissora- M.S. Student, Department of Veterinary BioSciences, OSU. (Graduated in 2005)

2) Justin Staubli, Integrated Biomedical Graduate Program, OSU (2010).

Doctoral Students (general examination committee member)

1) Maria Luz Lara-Marquez M.D. Ph.D. program, Department of Molecular Virology, Immunology and Medical Genetics (1999)

2) Carl Eugene Allen, M.D. Ph.D. Student, Molecular Cellular and Developmental Biology (MCDB) Program (2000)

3) K. Usha-Ph.D student, Department of Biochemistry, Avinashilingam Institute for Home Science and Higher education for Women (Deemed University) Coimbatore, India-External Member of the Dissertation Committee (1999)

4) Wei Ding, Ph.D. Student, Department of Veterinary BioSciences, Molecular Cellular and Developmental Biology (MCDB) Program

5) Jeffrey Sall- M.D., Ph.D. Student, Neuroscience Program (1999)6) Uma Sankar- Ph.D. Student, Department of Molecular Genetics

Molecular Cellular and Developmental Biology (MCDB) Program (2003)

7) Butch Stanley DVM- Ph.D. student, Department of Veterinary BioSciences (2002)

8) Joung-Woo Hong, Ph.D student, The Ohio State University Biochemistry Program (2004)

9) Seung Jae Kim, Department of Veterinary Biosciences (2003)10) Amritraj Nair, Dept.of Veterinary BioScience (2004)11) Hajime Hiraragi, Department of Veterinary BioSciences (2005)

8


12) Lee Silvermann, Dept of Veterinary Biosciences (2005)13) Hao-Tian Zhao, Molecular Cellular and Developmental Biology

(MCDB) Program (2004)14) Laurie Milward, Integrated Biomedical Graduate Program (2001)15) Nicholas Kin, Integrated Biomedical Graduate Program (2002)16) Xiaobin Zhao, School of Pharmacy, The Ohio State University

(2007)17) Qing Liu, School of Pharmacy, The Ohio State University (2008)18) Georgia Triantafillou, Integrated Biomedical Graduate Program,

The Ohio State University (2008).19) Sarwish Rafiq, Integrated Biomedical Graduate Program, The

Ohio State University (2010).20) Chi-ling Chiang-IBGP Program OSU (2012)21) Bo Yu, College of Engineering, The Ohio State University (2010).22) Rebekah Browning, Integrated Biomedical Graduate Program,

OSU (2012).23) Priscilla Lee, Molecular Cellular and Developmental Biology

(MCDB) Program, OSU (2012)24) Zhiliang Xie, Molecular Cellular and Developmental Biology

(MCDB) Program, OSU (2012)25) Jennifer Yang, Molecular Cellular and Developmental Biology

(MCDB) Program, OSU (2013)26) Paul David Ciarlariello, Molecular Cellular and Developmental

Biology (MCDB) Program, OSU (2013)27) Jennifer Yang, Molecular, Cellular and Developmental Biology

(MCDB) Program, OSU (2014)28) Aaron Victor, Medical Scientist Training Program (MSTP), OSU

(2014)29) Xiomeng Huang, Molecular, Cellular and Developmental Biology,

OSU (2014)

Graduate Student Faculty Representative:

1) Anne Lacombe Veronque, Department of Veterinary Clinical Sciences (2001)

2) Dimuth Siritunga, Plant Cellular and Molecular Biology (2002)3) Dennis Mehay, Linguistics (2012)4) Kristina Escondo, Spanish & Portuguese (2014)

Medical and Undergraduate Trainees:

1) Jon Eisengard M.D. 3rd year student- Academic Research elective (Su 1998)

2) Dr. Mohamed Bayoumy M.D.- Hem/Onc Fellow, Children’s Hospital (2000-2003)

9


3) David Motto- Undergraduate Student from University of Miami, Oxford, OH. (Su 1998)

4) Blaine Washington- Undergraduate Student, OSU (Su 2001)5) Rebekah Browning, Medical Student, OSU (Co-mentor) 6) Kyle Beckwith, MD/PhD Student, OSU (Mentor)7) Danielle Chappell, Undergraduate Student, OSU 8) Joseph Sweeney, Fordham University (2011)9) Nisitha Sengottuvel, Undergraduate Student, OSU (2012)10) Dhebamalini Murugam, Undergraduate Student, OSU (2013)11) Necrisha Roach, Medical Student, OSU Class of 2016, ASH

Minority Medical Student Scholar 2013

Junior Faculty Mentorship team:

1) Sumithira Vasu, MBBSAssistant Professor of Internal Medicine, Division of Hematology The Ohio State University

2) Samantha M. Jaglowski, MD, MPHAssistant Professor of Internal Medicine, Division of Hematology The Ohio State University

3) Jennifer A. Woyach, MD

Assistant Professor of Internal Medicine, Division of Hematology The Ohio State University

4) Flavia Pichiorri, PhDAssistant Professor of Internal Medicine, Division of Hematology

The Ohio State University

High School Teachers:

1) Thomas Trang- West High School, Columbus, OH June-Aug. 19982) Greg Hatofsky- Marion-Franklin High School, Columbus, OH

June- Aug. 1999

Others:1) Sangeetha Parolkhar-A high school student researcher- Corbin, KY2) Sangram Mehrothra- A work study under-graduate student of The

University of Kentucky3) Usha Govindarajulu- A high school Student Researcher 4) Frank Frissora, Girish Rajgolikar, Lisa Kegley, Cynthia Clendenin

and Monchai Chanyangam- Research Assistants5) Asha Ramanunni, Carolyn Cheney, Frank Frissora – Research

Associates

10


Student Achievement:

1) Kyle Beckwith – Received the Pelotonia Graduate Fellowship Award. April, 2014

2) Nisitha Sengottuvel - Received the Pelotonia Graduate Fellowship Award. April, 2014

3) Priscilla Do - Received the Pelotonia Graduate Fellowship Award. April, 2014

RESEARCH PUBLICATIONS:

Manuscripts in print or in press (# indicates manuscripts in which I served as a first, senior, co-first or co-senior author. IF-impact factors in parenthesis)*indicates both authors contributed equally to this manuscript

1. #Muthusamy N, Udhayakumar V, Krishnaraju K and Muthukkaruppan VR. Role of outer membrane proteins in immunity against murine salmonellosis.I. Antibody responses to crude outermembrane proteins of Salmonella typhimurium. Comp. Immun. Microbiol. Infect. Dis. (1985) 8:9-16. (IF 6.747)

2. Goud SN, Muthusamy N, Subbarao B. Differential responses of B cells fromthe spleen and lymphnode to TNP-Ficoll. J Immunol. (1988) 140:2925-2930. (IF 5.646)

3. Nagarkatti PS, Seth A, Nagarkatti M, Muthusamy N, Rychlik B, Subbarao BA. Specific defect in the proliferative capacity of B cells from old mice stimulated with autoreactive T cells. Cell. Immun. (1989) 120:102-11. (IF2.698)

4. #Muthusamy N, Baluyut AR, Subbarao B. Differential regulation of surface immunoglobulin and Lyb2 mediated B cell activation by cAMP.I. Evidence for alternative regulation of signaling through two different receptors linked to phosphatidylinositol hydrolysis in murine B cells. J Immunol. (1991) 147:2483-2492.

(IF5.646)

5. #Muthusamy N and Subbarao B. Differential regulation of surface immunoglobulin and Lyb2 mediated B cell activation.II. cAMP dependent (prostaglandin E2) and independent (IFN-g) mechanisms of regulation of B lymphocyte activation. International Immunologyy (1993) 5:949-956 (IF 3.403)

6. #Muthusamy N, Barton K , Leiden, JM. Defective activation and survival of T cells lacking the Ets-1 transcription factor. Nature (1995) 377:639-642. (IF 34.480)

7. #Barton K and Muthusamy N. (Co-first author), Chanyangam, M, Fisher, C, Clendenin, C and Leiden, JM. A severe defect in T cell proliferation and IL-2

11


production in transgenic mice expressing a dominant negative from of CREB transcription factor. Nature (1996) 379:81-85 (IF 34.480)

8. Su GH, Chen H-M, Muthusamy N, Tenen DG, Simon MC. Disruption of the gene encoding Spi-B, an Ets protein causes defective B cell receptor mediated responses. EMBO Journal (1997), 7118-7129. (IF 8.993)

9. Barton K, Muthusamy N, Fisher C, Chao N-T, Lannier L, Leiden, J. The Ets-1 Transcription Factor is Required for the Development of the Natural Killer Cell Lineage in Mice. Immunity (1998) 9:555-563. (IF 19.266)

10. Venkatraman C, Muthusamy N, Muthukkumar S, Bondada S. Signaling through murine CD72 receptor induces tyrosine phosphorylation of phospholipase C-2 independent of Syk activation. J. Immunol. (1998) 160:3322-3329 (5.646)

11. #Muthusamy N and Leiden JM. A protein kinase C, Ras and RSK2-dependent signal transduction pathway activates the cAMP responsive element binding protein transcription factor following T cell receptor engagement. J. Biol. Chemistry (1998) 273:22841-22847. (IF 5.328)

12. #Bayoumy M, Sankar U, Muthusamy N. (2002) Role of Macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis of bone marrow derived stem cells. I.J. Exp. Biol (2002) 40: 995-1000.

13. Ding W, Albrecht B, Kelley RE, Muthusamy N, Kim SJ, Altschuld RA, Lairmore, MD. Human T-Cell Lymphotropic Virus Type 1 p12I Expression Increases Cytoplasmic Calcium To Enhance the Activation of Nuclear Factor of Activated T-Cells. J. Virology (2002) 76:10374-82. (IF 5.150)

14. Allen CE, Muthusamy N, Weisbrode SE, Hong JW, Wu L-C . Developmental Anomalies and Neoplasia in Animals and Cells Deficient in the Large Zinc Finger Protein KRC. Genes, Chromosomes & Cancer (2002) 35:287-98. (IF 3.858)

15. #Chen, H-C, Durbin, J, Muthusamy, N. Activation Induced Differential Regulation of Stem Cell Antigen-1 (Ly-6A/E) Expression in Murine B Cells Cell. Immunol. (2003) 225(1):42-52 (IF 2.698)

16. #Frissora F, Chen H-C, Durbin,J, BondadaS, Muthusamy N. Interferon-gamma mediated inhibition of antigen receptor induced B cell proliferation and CREB-1 binding activity requires STAT-1 transcription factor. Eur. Journ. Immunol.(2003) 33:907-12. (IF5.179)

17. #Muthusamy N , Park DJ, Rho HW., Rhee SG, Bondada S. Impaired antigen receptor induced calcium mobilization in a phospholipase C-1 deficient B cell line. Immunol Lett. (2003) 90:203-7. (IF 2.906)

12


18. Johnson AJ, Lucas DM, Muthusamy N, Smith LS, Edwards, RE, De Lay, M., Croce, CM, Grever, MR, Byrd, JC. Characterization of the TCL-1 Transgenic Mouse as a Pre-Clinical Drug Development Tool for Human Chronic Lymphocytic Leukemia. Blood (2006) 108:1334-8 (IF 10.555)

19. #Chen H-C, Byrd JC, Muthusamy, N. Transgenic mice over-expressing a dominant negative cyclic AMP response element binding protein reveal a differential role for CREB-1 transcription factor in multiple stages of B cell development, maturation and survival Journal of Immunology (2006) 176:2208-18. (IF 5.646)

20. Saini SS, Farrugia W, Muthusamy N, Ramsland PA, Kaushik AK. Structural evidence for a new IgG1 antibody sequence allele of cattle. Scand J Immunol. 2007 Jan;65(1):32-8. (IF 2.108)

21. Zhao XB, Muthusamy N, Byrd JC, Lee RJ. Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes. J Pharm Sci. 2007 Sep;96(9):2424-35. (IF 2.906)

22. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007 Sep;117(9):2408-21. (IF 15.387)

23. Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, Caligiuri MA, Leone G. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15400-5.

(IF 9.432)

24. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007 Oct 1;110(7):2569-77. (IF 10.555)

25. Allen CE, Richards J, Muthusamy N, Auer H, Liu Y, Robinson ML, Barnard JA, Wu LC. Disruption of ZAS3 in mice alters NF-kappaB and AP-1 DNA binding and T-cell development. Gene Expr. 2007;14(2):83-100. (IF 1.548)

26. Zhao X, Wu J, Muthusamy N, Byrd JC, Lee RJ. Liposomal coencapsulatedfludarabine and mitoxantrone for lymphoproliferative disorder

treatment.J Pharm Sci. 2008 Apr;97(4):1508-18. (IF 2.906)

13


27. # Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N, Byrd JC. FTY720 demonstrates promising

preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 2008 Jan 1;111(1):275-84. (IF 10.555)

28. #Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. IL-21 mediates apoptosis through up- regulation of the BH3 family member BIM and enhances both direct and antibody- dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 2008 May 1;111(9):4723-30. (IF 10.555)

29. #Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res. 2008 Jan 15; 14(2):569-78. (IF 6.177)

30. Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, Muthusamy N, Byrd JC, Cheng AL, Chen CS. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res. 2008 Feb 15;68(4):1204-12. (IF 7.543)

31. Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ,Grever MR, Byrd JC, Dalton JT, Phelps MA. Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. Ther Drug Monit.. 2008 Oct;30(5):620-7

32. Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.Blood. 2008 Dec 15;112(13):5180-9. (IF 10.555)

33. Nagaleekar VK, Diehl SA, Juncadella I, Charland C, Muthusamy N, Eaton S, Haynes L, Garrett-Sinha LA, Anguita J, Rincón M. IP3 receptor-mediated Ca2+ release in naive CD4 T cells dictates their cytokine program. J Immunol. 2008 Dec 15;181(12):8315-22. (IF 3.403)

34. #Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. The humanized

CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukemia. Br J Haematol. 2009

Jan 12 . (IF 4.597)

14


35.Yang X, Koh CG, Liu S, Pan X, Santhanam R, Yu B, Peng Y, Pang J, Golan S, Talmon Y, Jin Y, Muthusamy N, Byrd JC, Chan KK, Lee LJ, Marcucci G, Lee RJ. Transferrin Receptor-Targeted Lipid Nanoparticles for Delivery of an Antisense

Oligodeoxyribonucleotide against Bcl-2. Mol Pharm. 2009 Feb 2;6(1):221-230. (IF 4.531)

36. Joshi T, Ganesan LP, Cheney C, Ostrowski MC, Muthusamy N, Byrd JC, Tridandapani S. The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma. PLoS ONE. 2009;4(1):e4208.. (IF 4.351)

37. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff

M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G. MicroRNA – 29b induces global DNA hypomethylation and tumor suppressor gene. Blood. 2009

Feb 11 (IF 10.555).

38. Wei R, Srinivasan R, Cantemir-Stone CZ, Sharma SM, Santhanam R, Weinstein M, Muthusamy N, Man AK, Oshima RG, Leone G, Ostrowski MC. Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood. 2009; 114:1123-1130 (IF 10.555).

39. Chan K, Liu, Z , Zhiliang X, Ming C; Wang H, Liu S, Triantafillou G, Garzon R, Croce C, Byrd JC, Muthusamy N, Marcucci G . A Novel Ultrasensitive

Hybridization-Based ELISA Method for 2-Methoxyphosphorothiolate microRNAs and its in vitro and in vivo Application. AAPS J. 2010 Dec;12(4):556-68. (IF 5.5)

40.Jin Y, Liu S, Yu B, Godan S, Koh C-G, Yang J, Huynh L, Yang Z, Pang J, Muthusamy N, Chan K, Byrd J, Talmon Y, Lee L, Lee R, Marcucci G. Targeted Delivery of Antisense Oligodeoxynucleotide by Transferrin Conjugated pH-Sensitive Lipopolyplex Nanoparticles: A Novel Oligonucleotide Based Therapeutic Strategy in Acute Myeloid Leukemia. Mol Pharm. 2010 Feb 1;7(1):196-206. (IF 5.408). (IF

4.531)

41.Koh CG, Zhang X, Liu S, Golan S, Yu B, Yang X, Guan J, Jin Y, Talmon Y, Muthusamy N, Chan KK, Byrd JC, Lee RJ, Marcucci G, Lee LJ. Delivery of

antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing. J Control Release. 2010 Jan 4;141(1):62-9. (IF 5.949)

42.#Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain engineered monoclonal antibody. Blood. 2010 Feb 11; 115(6):1204-13 (IF 10.555).

15


43.#Gowda A, Ramanunni A, Cheney C, Rozewski D, Kindsvogel W, Lehman A, Jarjoura D, Caligiuri M, Byrd JC, Muthusamy N. Differential effects of IL-2 and IL-21 on expansion of the CD4(+)CD25(+)Foxp3(+) T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia. MAbs. 2010 Jan;2(1):35-41.

44.#Biswas S, Zhaob XB, Monea AP, Moc X, Vargo M, Jarjoura D, Byrd JC, Muthusamy N. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leukemia Research Jul;34(7):925-31. Epub 2010 Feb 19 (IF 2.358)

45. Butchar JP, Mehta P, Justiniano SE, Guenterberg KD, Kondadasula S-V, Mo X, Chemudupati M, Kanneganti T-D, Amer A, Muthusamy N, Jarjoura D, Marsh CB, Carson, WE III, Byrd JC, Tridandapani S. Reciprocal Regulation of Activating and Inhibitory Fc Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy. Clin. Cancer Res. published 23 March 2010, 10.1158/1078- 432.CCR-09-2591 (IF 6.747)

46. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum K, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen C-S, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway. Blood. 2010; 115:2619-2629 (IF 10.555).

47. Leshchenko VV, Kuo P-Y, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh SK, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy N, Kahl BS, Byrd JC, Wiestner A, Melnick A, Parekh S. Genome wide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010;116(7):1025-34. (IF 10.555)

48. #Liu Q, Alinari L, Chen C-S, Yan F, Dalton J, Lapalombella R, Zhang Xiaoli, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N. FTY20 Demonstrates Promising In-Vitro and In-vivo Pre-clinical Activity by Down-modulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma. Clinical Cancer Research 2010 16:3182-3192. (IF 6.747)

49. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The Clinical Application of Monoclonal Antibodies in Chronic Lymphocytic Leukemia. 2010 Blood 116:3705-3714 (IF 10.555).

50. Hertlein E, Triantafillou G, Sass EJ, Hessler J, Zhang X, Jarjoura D, Lucas DM, Muthusamy N, Goldenberg DM, Lee RJ, Byrd JC. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. 2010 Blood (IF 10.555) 116:2554-2558.

16


51. Lesinski GB, Carson WE, Repasky EA, Wei WZ, Kalinski P, Lotze MT, June CH, Petros W, Muthusamy N, Olencki T.Meeting Report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010. J Immunother 33(7):659-662, 2010 (IF 3.23)

52. #Bai L-Y, Ma Y, Kulp SK, Wang S-H, Chiu C-F, Frissora F, Mo X, Jarjoura D, Byrd JC, Chen C-S, Muthusamy N. OSU-DY7, a Novel D-tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma Through p38 Mitogen-Activated Protein Kinase Pathway. British Journal of Haematology. 2011, 153(5):623-33 (IF 4.597)

53. Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Praetorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocch RA. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011, (17):4530-41 (IF 10.555)

54. Herman SEM, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, Zhang X, Lannutti BJ, Puri KD, Muthusamy N, Byrd JC, Johnson AJ. Activation of the Phosphatidylinositol 3-kinase Pathway in CLL is Essential for the Immunomodulatory Effects of Lenalidomide. Blood. 2011, 117(16):4323-7 (IF: 10.555)

55. Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D, Kogure T, Patel T, Terracciano L, Muthusamy N, Byrd JC, Kulp SK, Chen CS. Antitumor effects of OSU-2S, a non-immunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 2011, 53(6) 1943-58 (IF 10.840)

56.# Muthusamy N, Breidenbach H , Andritsos L , Flynn J, Jones J, Ramanunni A, Mo X, Jarjoura D, Byrd JC, Heerema NA. Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. Cancer Genetics 2011 Feb;204(2):77-83. (IF 1.551)

57.#Muthusamy N, Chen H-C, Rajgolikar G, Butz KG, Frissora F, Gronostajski RM. Recombination Activation Gene-2 deficient Blastocyst Complementation Analysis Reveals an Essential Role for Nuclear Factor I-A Transcription Factor in T cell Activation. International Immunology 2011 Jun;23(6):385-90. (IF 3.403).

58. Alinari, L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani, R, Mao Y, Yu B, QuinionC, Towns WH, Chen C-S, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Praetorius-Ibba M, Baiocchi RA. FTY720 increases CD74 expression and Sensitizes mantle cell lymphoma cells to Milatuzumab-mediated cell death. Blood 2011 118:6893-6903 (IF 10.555).

17


59. # Fisher IB, Ostrowski MC, Muthusamy N. Role for Ets-2threonine72 in stage specific thymocyte development and survival. J Biol Chem. 2012 Feb 17;287(8):5199-210. (IF 5.328)

60. # Lapalombella R, Yeh, Y-Y, Wang L, Ramanunni A, Jha S, Staubli J, Lucas DM, Mani R, Herman SEM, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn J, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen C-S, Lozanski G, Heerema N, Tridandapani S, Freitas MA, Muthusamy N, Byrd, JC. Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Cancer Cell 2012;21(5):694-708 (IF 26.925)

61. Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang C-H. Dual-targeting immunotherapy of lymphoma; Potent cytotoxicity of anti-CD20-CD74 bispecific antibodies in mantle cell and other lymphomas. Blood. 2012; 119:3767 (IF 10.558)

62. #Rafiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JC. XmAb-5574 antibody demonstrates superior antibody dependent cellular cytotoxicity as compared to CD52 and CD20 targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia 2012, 26(7):1720-2. (IF 8.966)

63. Wang H, Chiu M, Xie Z, Chiu M, Liu Z, Zhongfa C, Liu Z, Chen P, Liu S, Byrd JC, Muthusany N, Garzon R, Croce C. Marcucci G, Chan KK. Synthetic microRNAs Cassette Dosing: Pharmacokinetics, Tissue Distribution and Bioactivity” Molecular Pharmaceutics 2012;9(6):1638-44. (IF 5.40)

64.Timmerman JM, Byrd JC, Andorsky DJ, Yamada R, Kramer J, Muthusamy N, Hunder N, Pagel JM. A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders. Clin. Cancer Res. 2012; 18:5752-5760 (IF 7.742)

65. Yu B, Mao Y, Bai L-Y, Herman SEM, Ramanunni A, Mo X, Jin Y, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. Targeted Nanoparticle Delivery Overcomes Off-Target Immunostimulatory Effects of Oligonucleotides and Improves Therapeutic Efficacy. Blood 2013; 121:136-147 (IF 10.558)

66. Raghunandan R and Muthusamy N. Modulation of Ets-1 expression in B lymphocytes is dependent on the antigen receptor mediated activation signals and cell cycle status. Scandavian Journal of Immunology 2013 Feb;77(2):75-83 (IF 2.230)

67. Mao Y, Triantafillou G,, Hertlein E, Towns W, Stafanovski M, Jarjoura D, Phelps M, Marcucci G, Lee RJ, Byrd JC, Muthusamy N. Milatuzumab Liposome as a Dexamethasone Carrier Demonstrates Superior Tumor Targeting in vivo in a Pre-Clinical Xenograft Model of CD74+ Lymphoid Lymphoma. Clin Cancer Res. 2013 Jan 15;19(2):347-56 (IF 7.742)

18


68. Baskar S and Muthusamy N. Antibody-based therapeutics for the treatment of human B cell malignancies. Curr Allergy Asthma Rep. 2013 Feb;13(1):33-43. (IF 2.500)

69. Raghunandan R, Frissora FW, Muthusamy N. Modulation of Ets-1 expression in B lymphocytes is dependent on the antigen receptor-mediated activation signals and cell cycle status. Scand J Immunol. 2013 Feb;77(2):75-83 (IF 2.230)

70. Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC. Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties. J Immunol. 2013 Mar 15;190(6):2702-11 (IF 5.788)

71. Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic RB, Walker A, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G. Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. Clin Cancer Res. 2013 May 1;19(9):2355-67 (IF 7.742)

72. Yu B, Mao Y, Yuan Y, Yue C, Wang X, Mo X, Jarjoura D, Paulaitis ME, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials. 2013 Aug;34(26):6185-93 (IF 7.604)

73. Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy N. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies. mAbs. 2013 Sep-Oct;5(5):723-35 (IF 5.275)

74. Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani S. FcγR-induced soluble VEGFR-1 production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies. J Biol Chem. 2013 Sep 13;288(37):26800-9 (IF 4.651)

75. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. Blood. 2013 Oct 10;122(15):2539-49 (IF 9.060)

19


76. Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy N. Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Blood. 2013 Nov 7;122(19):3308-16 (IF 9.060)

77. Wu Y, Kwak KJ, Agarwal K, Marras A, Wang C, Mao Y, Huang X, Ma J, Yu B, Lee R, Vachani A, Marcucci G, Byrd JC, Muthusamy N, Otterson G, Huang K, Castro CE, Paulaitis M, Nana-Sinkam SP, Lee LJ. Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons. Anal Chem. 2013 Dec 3;85(23):11265-74. (IF 5.695)

78. #Mao Y, Wang J, Zhao Y, Wu Y, Kwak KJ, Chen CS, Byrd JC, Lee RJ, Phelps MA, Lee LJ, Muthusamy N. A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery. Nanomedicine. 2014 Feb;10(2):393-400 (IF 5.260).

79. Stephens DM, Rupert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia. 2014 Jun;28(6): 1365-8. (IF 10.164)

80.# Cheney CM*, Stephens DM*, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O’Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. mAbs, 2014 May 1;6(3):748-54 (IF 5.275)

81. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014 Mar 20;123(12):1957-60. (IF 9.060)

82. Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10. (IF 10.164)

83. Mani R, Mao Y-C, Frissora FW, Chiang C-L, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn JM, Jones JA, Andritsos LA, Baskar S, Rader C, Phelps MA, Chen C-S, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia. Leukemia 2014 Jun 20. doi: 10.1038/leu.2014.199. [Epub ahead of print] (IF 10.164)

20


84. #Mao Y-C, Wang J, Zhao Y, Yan R, Li H, Chen C-S, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Phelps MA. Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2014 Sep;98:160-5

85. Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Oct 1. pii: 75328. doi: 10.1172/JCI75328. [Epub ahead of print] (IF 13.765)

86. Motiwala T, Kutay H, Zanesi N, Frissora F, Mo X, Muthusamy N, Jacob S. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model. Leukemia. (In Press)

87. Chang L, Howdyshell M, Liao Wei-Ching, Chiang Chi-Ling, Gallego-Perez Daniel, Yang Z, Lu W, Byrd JC, Muthusamy N, Lee LJ, Sooryakumar R. Magnetic tweezers-based 3D microchannel electroporation for high-throughput gene transfection in living Cells. Small. 2014 Nov doi:10.1002/smll.201402564.

Manuscripts in Submission(# indicates manuscripts in which I served as a first, senior, co-first or co-senior author. IF-impact factors in parenthesis)*indicates both authors contributed equally to this manuscript

1. Xu S, Quan J, Li H, Yung BC, Pang J, Zhou C, Cho YA, Zhang M, Liu S, Muthusamy N, Chan KK, Byrd JC, Lee LJ, Marcucci G, Lee RJ .CD33-targeted lipid nanoparticles (aCD33LNs) for therapeutic delivery of GTI-2040 to acute myelogenous leukemia.

2. #Beckwith KA, Byrd JC, Muthusamy N. Tetraspanins as Therapeutic Targets in Hematological Malignancy: A Concise Review

3. Alhakeema SS, Sindhavab VJ, McKennaa MK, Gachukia BW, Byrd JC, Muthusamy N, Bondada S. Role of B cell receptor signaling in IL-10 production by normal and malignant B-1 cells.

4. Heerema NA, Muthusamy N, Ruppert AS, Andritsos LA, Grever MR, Jones JA, Maddocks KJ, Byrd JC. Prognostic Significance of Cytogenetic Complexity and del(17p) at Diagnosis of Chronic Lymphocytic Leukemia.

5. Mani R, Chiang CL, Frissora FW, Yan R, Mo Χ, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, and Muthusamy N. ROR1 targeted

21


delivery of OSU-2S, exerts potent cytotoxicity in mantle cell lymphoma in-vitro and in-vivo.

6. Browning RL, Mo X, Muthusamy N, Byrd JC. CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway

Books and Proceedings:

1. Subbarao B, Baluyut AR and Muthusamy N. Functionally important B cell surface molecules. In T cell dependent and independent B cell activation (ed. E.C.Snow) CRC Press, Inc. Boston (1990).

2. Chen, H-C, Frissora, F and Muthusamy, N. A Transgenic Approach to Define the Role of Cyclic AMP Response Element Binding Proteins in B Cells.10th Int. Congress of Immunology, New Delhi, India, 1998 Proceedings. Monduzzi Editore S.p.A-Bologna, Italy.

3. Zhao XB, Muthusamy N, Byrd JC and Lee RJ, Folate receptor-targeted liposomes for cancer therapy. In Amiji MA editor. Nanotechnology for cancer therapeutics, Boca Raton, FL, CRC Press,2006.

4. Wu H, Muthusamy N, Bondada S. CD72 in Choi S Encyclopedia of Signaling Molecules, New York, Springer; forthcoming (2012)

Ph.D THESIS:

Differential regulation of B lymphocyte activation mediated through surface Immunoglobulin and Lyb2 molecules (University of Kentucky, Lexington, KY. 1992).

INVENTIONS DISCLOSURES:

1) 1996-UCHI # 635- Ets-1 -/- 1 mice. Natarajan Muthusamy, Kevin Barton, Cynthia Clendenin, Kristine Sigrist and Jeffrey Leiden (Co-Inventor- University of Chicago Invention disclosure filed on Oct 21, 1996).

2) 1996- UCHI # 634- CREB-A119 transgenic mice. Natarajan Muthusamy, Kevin Barton, Cynthia Clendenin, Jeffrey Leiden (Co-Inventor- University of Chicago Invention disclosure filed on Oct 21, 1996 and elected for commercialization by ARCH Development Corporation on Dec 19, 1996).

3) 2006-A novel application of IL-21 in rendering enhanced responsiveness to chemotherapy and Antibody mediated therapy in treatment of Chronic lymphocytic Leukemia, ALL, and NHL. John Byrd, Natarajan Muthusamy and Aruna Gowda. (Co-inventor).

22


4) 2006- FYT720 as a therapeutic agent for CML-Danilo Perrotti, John Byrd, Ching-Shih Chen, Natarajan Muthusamy (Co-inventor).

5) 2006-FTY720 as a Novel Therapeutic Agent for CLL, ALL, and B-cell Non Hodgkin's Lymphoma that Works Independent of BCL-2 through a PP2A Activation Mechanism of Action; John Byrd, Ching-Shih Chen, Natarajan Muthusamy, Danilo Perrotti. (Co-inventor).

6) 2007-CD74-Targeted Immunoliposomal Mitoxantrone for Chronic Lymphocytic Leukemia Therapy; John Byrd, Robert Lee, Natarajan Muthusamy, Xiaobin Zhao. (Co-inventor).

7) 2007-TCL-1 Transgenic Mouse as a Model for Chronic Lymphocytic Leukemia. John C. Byrd, Amy Johnson, Christoph Plass, David Lucas and Natarajan Muthusamy (Co-inventor).

8) 2007-Sensitive Hybridization Quantitation Method for Modified and Non-modified microRNA and DNA based oligonucleotides. Kenneth K. Chan, John C. Byrd, Guido Marcucci, Zhongfa Liu, Zhiliang Xie, Natarajan Muthusamy, Shujun Liu, and Ramiro Garzon (Co-Inventor).

9) 2007-A novel liposomal formulation of CpG oligonucleotides for immunotherapy. Robert Lee, John Byrd, Natarajan Muthusamy and Yanhui Liu (Co-inventor).

10) 2010- Novel protein kinase C delta activators. Ching-Shih Chen, Samuel K Kulp, Dansheng Wang, John Byrd and Natarajan Muthusamy (Co-inventor).

11) 2012- FTY720-Derived Anticancer Agents. Ching-Shih Chen, Samuel Kulp, Dasheng Wang, J C Byrd, Natarajan Muthusamy (Co-inventor). Application # 13/305,927 US patent 8,309,768 issued November 13, 2012.

12) 2013 – FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death. Lapo Alinari, Robert Baiocchi, Natarajan Muthusamy (Co-inventor). Application # 13/551,886 US patent 8,591,892 November 26, 2013.

13) 2012 – Therapeutic agents for the treatment of lymphoid malignancies. John Cyrd, Danilo Perrotti, Ching-Shih Chen, James Dalton, Frank Frissora, Xiaobin Zhao, Qing Liu, Natarajan Muthusamy (Co-inventor). US Patent 8,318,812 issued November 27, 2012

14) 2013 – Anti-CD33 Antibody Therapy in Combination with Azanucleoside and Immunemodulatory Agents for AML. Carolyn Cheney, Shun He, Guido Marcucci, Natarajan Muthusamy (Co-inventor). Tech ID#2014-015

23


15) 2014 – R0R1 targeted deliveryof FTY720 derivatives, therapeutics and other biologicals to R0R1+cells using nanoparticle formulations. Natarajan Muthusamy, Rajeswaran Mani, John C. Byrd, Lee,. Tech ID#T2015-112

SELECTED ABSTRACTS (* indicates peer reviewed)

1. Muthusamy N , Udhayakumar V, Krishnaraj K, Muthukkaruppan, VR. Antibody response to outer membrane proteins of Salmonella typhimurium. Annual Meeting, Indian Immunology Society, Hydrabad. 1984.*

2. Goud SN, Muthusamy N Subbarao B. Differential responses of lymph node and splenic B cells to TNP-Ficoll (Oral presentation). MidWest Autumn Immunology Conference, Chicago, IL. November, 1986.*

3. Goud SN, Muthusamy N, Subbarao B. Differential abilities of lymph node and splenic B cell response to TNP-Ficoll. Federation Proc. 46:5215:1987.*

4. Subbarao B, Udhayakumar V, Muthusamy N, Cross RA, Seth M, Nagarkatti M, Nagarkatti, P. Abnormalities of intrinsic B and T lymphocyte function in old mice. 5th International symposium on infections in the immuno compromised host. Noordwijkerhout, The Netherlands. June 5-8, 1988.*

5. Subbarao B, Muthusamy N, Seth A, Nagarkatti M, Nagarkatti, P. A specific defect in the ability if B-lymphocytes from old mice to proliferate in response to stimulation with an auto reactive T cell clone. FASEB Journal 2: A1664. 1988.*

6. Muthusamy N , Baluyut AR, Subbarao B. Differential effects of cAMP and on anti-IgM and anti-Lyb2 mediated B cell activation (Oral presentation). MidWest Immunology Conference, St. Louis, MO. 1988.*

7. Muthusamy N , Govindarajulu U, Waller WE, Baluyut AR, Subbarao B. Differential effects of cAMP on anti-u and anti-Lyb2 mediated B cell activation. Eastern Student Research Forum, Miami, FL. March 1989.*

8. Muthusamy N , Baluyut AR, Subbarao, B.Evidence for alternative signal transduction mechanisms in murine B cells (Oral presentation). MidWest Immunology Conference, St. Louis, MO. 1989.*

9. Muthusamy N , Govindarajulu U, Waller WE, Baluyut AR, Subbarao B. Differential effects of cAMP on anti-IgM and anti-Lyb2 mediated B cell activation (Oral presentation). FASEB meeting, New Orleans,LA. 1989.*

10. Baluyut AR, Muthusamy N, Subbarao, B. The role of surface Ia molecules in B cell activation. Seventh International Congress of Immunology, Berlin, FRG. July-August, 1989.*

24


11. Muthusamy N , Baluyut AR, Subbarao B. Differential regulation of B lymphocyte responses. Graduate Research Forum, University of Kentucky. November, 1990 *

12. Muthusamy N , Baluyut AR, Subbarao, B. Differential regulation of surface IgM and Lyb2 mediated B cell activation-evidence for alternative mechanisms of inositol triphosphate generation in murine B cells. FASEB meeting, New Orleans, LA. 1990.*

13. Muthusamy N and Subbarao B. Triggering of murine B-lymphocytes via Lyb2 surface molecules results in a rapid induction of tyrosine phosphorylation. FASEB meeting, 1991. Atlanta, GA.*

14. Muthusamy N and Subbarao, B. Differential regulation of early signaling in B-lymphocytes by cAMP. Cold Spring Harbor Laboratory, 56th symposium on Quantitative Biology. The Cell Cycle. May 29-June 5, 1991.*

15. Subbarao B and Muthusamy N. Differential regulation of surface Immunoglobulin and Lyb2 mediated B cell activation. II. CAMP dependent and independent mechanisms of PGE2 and IFN-γ mediated regulation of B lymphocyte activation. FASEB meeting. Anaheim, CA. April 5-9, 1992.*

16. Muthusamy N , Park DJ, Rho HW, Rhee SG, Subbarao B. Differential expression of phospholipase C isozymes in murine B-lymphocytes. FASEB meeting, Anaheim, CA. April 5-9, 1992.*

17. Muthusamy N , and Subbarao B. Cyclic AMP dependent and independent mechanisms of prostaglandin E2 and interferon-γ mediated regulation of B cell activation through IgM and Lyb2 receptors. 8th International Congress of Immunology, Budapest, Hungary. Aug. 23-28, 1992.*

18. Muthusamy N , Barton K, Clendenin C, Chanyangam M, Leiden JM. Expression of dominant negative CREB transgene results in a severe defect in murine T cell activation. Cold Spring Harbor Laboratory Mouse Molecular Genetics Meeting. Aug. 31- Sept. 4, 1994.*

19. Su GH, Chen H-M, Muthusamy N, Tenens DG, Simon, MC. Disruption of the gene encoding Sip-B, an EST protein causes defective B cell receptor mediated responses -B lymphocytes in Health and Disease. Keystone Symposia, Steamboat Springs, CO. Jan.10-16, 1997.*

20. Muthusamy N , Barton K, Fisher C, Leiden, JM. Role of Ets-1 transcription factors in lymphocyte development and function. AAI Meeting, San Francisco, CA. Feb 28-March 5, 1997.*

21. Wolfgang CD, Allen AE, Liang, G, Vaessin H, Hai, T. Stress-Inducible Gene Expression. (November 12-15, Danvers, MA).*

25


22. Xie E, Barr F, Muthusamy N, Qualman S, Durbin, J. The Role of Pax3-FKHR fusion gene in the development of Alveolar Rhabdomyosarcoma. 19th Annual Children’s Hospital and Children’s Hospital Research Foundation Research Forum. June 4-5, 1998.

23. Chen H-C, Frissora F, Muthusamy N. A Transgenic Approach to Define the Role of Cyclic AMP Response Element Binding Proteins in B Cells. 19th Annual Children’s Hospital and Children’s Hospital Research Foundation Research Forum. June 4-5, 1998.

24. Rajgolikar G, Weslow-Schmidt J, Robinson M, O'Dorisio S, Muthusamy N. Generation of Gene Targeted Mutant Mice at CHRF. 19th Annual Children’s Hospital and Children’s Hospital Research Foundation Research Forum. June 4-5, 1998.

25. Frissora F, Chen H-C, Muthusamy N. Characterization of Antigen Receptor Induced B lymphocyte Growth Inhibition by IFN-γ. 19th Annual Children’s Hospital and Children’s Hospital Research Foundation Research Forum. June 4-5, 1998.

26. Chen H-C, Frissora F, Muthusamy N. Generation of Transgenic Mice to Define the Role of Cyclic AMP Response Element Binding Proteins in B Cells. 10th Annual Stone Lab Meeting, F.T. Stone Laboratory, Put-in-Bay, OH. Sept. 18-20, 1998.

27. Muthusamy N , Frissora F, Leiden, JL. A Protein Kinase C, Ras, and Rsk-2-Dependent Phosphorylation of CREB Transcription Factor by T Cell Antigen Receptor Stimulation. 10th Annual Stone Lab Meeting, F.T. Stone Laboratory, Put-in-Bay, OH. Sept. 18-20, 1998.

28. Chen H-C, Frissora F, Muthusamy N. A Transgenic Approach to Define the Role of cyclic AMP Response Element Binding Proteins in B Cells. 10th Int. Congress of Immunology, New Delhi, India, Nov 1-7, 1998.*

29. Chen H-C, Frissora F, Muthusamy N. Generation of Transgenic Mice to Define the Role of Cyclic AMP Response Element Binding Proteins in B Cells. OSUCCC Scientific Retreat, Newark, OH. Dec. 16, 1998.

30. Rajgolikar G, Weslow-Schmidt J, Robinson M, O'Dorisio S, Muthusamy N. Generation of Gene Targeted Mutant Mice. OSUCCC Scientific Retreat, Newark, OH. Dec. 16, 1998.

31. Frissora F, Chen H-C, Durbin J, Muthusamy N. Antigen Receptor Induced cAMP Response Element Binding Activity in Murine B Cells is Negatively Regulated by IFN-γ PAA/PAS Joint Meeting, Boston, MA. May 12-16, 2000.*

32. Chen H-C and Muthusamy N. Differential Regulation of Stem Cell Antigen-1 (Ly-6A/E) Expression during Murine B Cell Activation. PAA/PAS Joint Meeting, Boston, MA. May 12-16, 2000.*

26


33. Muthusamy N , Rajgolikar G, and Gronostajski R. RAG-2 Deficient Blastocyst Complementation Analysis Reveal an Essential Role for NF-IA Transcription Factor in T Cells. PAA/PAS Joint Meeting, Boston, MA. May 12-16, 2000.*

34. Chen H-C and Muthusamy N. A Transgenic mouse model reveals a role for CREB Transcription Factor in normal development of Bone Marrow and Peritoneal B cells. 21st Annual Children’s Hospital Research Forum, Columbus, OH. June 1–2, 2000.

35. Fisher IB, and Muthusamy N. In vivo and In vitro Approaches to Define the Role of Ets-2 Lymphocyte Development and Function. 21st Annual Children’s Hospital Research Forum, Columbus, OH. June 1–2, 2000.

36. Chen H-C Muthusamy N. Differential Regulation of Stem Cell Antigen-1 (Ly-6A/E) Expression during Murine B Cell Activation. 21st Annual Children’s Hospital Research Forum, Columbus, OH. June 1-2, 2000.

37. Frissora F, Chen H-C, Durbin J, Bondada S, Muthusamy N. Antigen receptor induced CREB signaling pathway in murine B cells is negatively regulated by IFNγ. 21st Annual Children’s Hospital Research Forum, Columbus, OH. June 1–2, 2000.

38. Chen H-C and Muthusamy N. A transgenic approach defines a differential role for cyclic AMP response element binding proteins in B-1 and B-2 B cell development. FASEB/American Association of Immunologists meeting, Orlando, FL. March 2001.*

39. Muthusamy N , Rajgolikar G, Butz KG, Chen H-C Frissora F, Gronostajski, RM. Blastocyst complementation analysis reveal a role for NF-1A transcription factor in T cell activation. FASEB/American Association of Immunologists meeting, Orlando, FL. March 2001.*

40. Fisher IB, Ostrowski M, Muthusamy N. Transgenic mice over expressing a non-phosphorylatable Ets-2 transcription factor reveal defective development of T cells in the thymus. PAA/PAS Joint Meeting, Baltimore, MD. April 2001.*

41. Chen H-C and Muthusamy N. A transgenic approach defines a differential role for cyclic AMP response element binding proteins in B-1 and B-2 B cell development. PAA/PAS Joint Meeting, Baltimore, MD. April 2001.*

42. Muthusamy N and Chen H-C. Role of cyclic AMP response element binding proteins in hematopoiesis-Lessons from transgenic mouse models. PAA/PAS Joint Meeting, Baltimore, MD. April 2001.*

43. Muthusamy N and Chen H-C. Role of cyclic AMP response element binding proteins in B cell development -Lessons from a transgenic mouse model. Keystone Symposia on B cells biology in diseases, Utah. April 17-April 22, 2001.*

27


44. Chen H-C and Muthusamy N. A transgenic approach defines a differential role for CREB transcription factor in B-1 and B-2 B cell development in Mice. Abstract. The Ohio State University 15th Annual Edward F. Hayes Graduate Research Forum. The Ohio State University, OH. April 21, 2001.*

45. Muthusamy N , Bayoumy M, Chen, H-C. Transcriptional control of osteoclast development and function by cyclic AMP binding protein- Lessons from a transgenic mouse model. The American Academy of Pediatrics Meeting, San Francisco, CA, October 19-24, 2002.*

46. Chen H-C and Muthusamy N. Differential role for CREB-1 transcription factor in regulation of B-1 and B-2 B cell development in mice. The Ohio State University Comprehensive Cancer Center Fourth Annual Scientific Meeting, Dublin, OH. Jan.11, 2002.

47. Natarajan A, Frissora F, Chen H-C, Raghunandan R, Kusewitt D, Muthusamy N. Analysis of splenocyte population in mice deficient in Ets-1 reveal selective expansion of macrophages, erythrocytes and B-1 B cells. The Ohio State University Comprehensive Cancer Center Fourth Annual Scientific Meeting, Dublin, OH. Jan.11, 2002.

48. Washington B, Frissora F, Fisher IB, Muthusamy N. Targeted gene deletion in mice reveals an essential role for Ets-1 transcription factor in T cell proliferation and survival. The Ohio State University Comprehensive Cancer Center Fourth Annual Scientific Meeting, Dublin, OH. Jan.11, 2002.

49. Fisher IB, Ostrowski M, Muthusamy N. Transgenic mice over-expressing a phosphomutant Ets-2 transcription factor reveal an increase in thymocyte cell death. The Ohio State University Comprehensive Cancer Center Fourth Annual Scientific Meeting, Dublin, OH. Jan.11, 2002.

50. Chen H-C and Muthusamy N. Differential role for CREB transcription of B-1 and B-2 B cell development in mice. The Ohio State University Medical Center, College of Medicine and Public Health, Graduate and Postgraduate Research Day, April 4, 2002.

51. Chen H-C and Muthusamy N. Differential role for CREB transcription of B-1 and B-2 B cell development in mice. Experimental Biology, Annual Meeting of The American Association of Immunologists 2002, New Orleans, LA. April 20-24, 2002.*

52. Chen H-C and Muthusamy N. Differential role for CREB transcription of B-1 and B-

2 B cell development in mice. CRI Retreat, Newark, OH. April 25-26, 2002.

53. Muthusamy N , Chen H-C, Bayoumy M. Role of cyclic AMP binding protein-1 in B lymphocyte and osteoclasts development and function-Lessons from a transgenic

28


mouse model. PAA/PAS Joint meeting, Baltimore, MD May 5, 2002.*

54. Bayoumy M and Muthusamy N. Timing of addition of M-CSF, TNF and ODF determine efficient in-vitro Osteoclastogenesis from bone marrow derived Stem cells. PAA/PAS Joint meeting, Baltimore, MD. May 05, 2002.*

55. Fisher I, Ostrowski M, Muthusamy N. Transgenic Mice Over-Expressing a Non-Phosphorylatable Ets-2 Transcription Factor Reveal an Increase in Thymocyte Cell Death. PAA/PAS Joint meeting, Baltimore, MD. May 06, 2002.

56. Muthusamy N , Rajgolikar G., Butz KG, Chen HC, Frissora F, Gronostajski R. Recombination Activation Gene-2 deficient Blastocyst Complementation Analysis Reveals an Essential Role for Nuclear Factor I-A Transcription Factor in T cell Activation. Autumn Immunology Conference, Nov 23-25, 2002 Chicago.*

57. Frissora F, Chen H-C, Durbin J, Bondada S, Muthusamy N. Cross-talk between the STAT-1/CREB signaling pathway in IFN- mediated negative regulation of B cell growth. Autumn Immunology Conference, Nov 23-25, 2002 Chicago.*

58. Fisher I and Muthusamy N. Transgenic Mice Over-Expressing a Phosphomutant Ets-2 Reveal An Increase in Thymocyte Cell Death. Autumn Immunology Conference, Nov 23-25, 2002 Chicago.*

59. Chen-HC and Muthusamy N. A Transgenic model reveals a role for CREB transcription factor in B cell development and differentiation. Autumn Immunology Conference, Nov 23-25, 2002 Chicago.*

60. Zhao XB, Biswas S, Mone A, Ledbetter J, Ledbetter MH, Grosmaire L, Espling E, Cheney C, Young D, Lee RJ, Muthusamy N, Byrd JC. Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells. ASH Annual Meeting Abstracts. 2004;104:2515.*

61. Muthusamy N , Chen H-C, Frissora F, Byrd JC. Generation and Analysis of Transgenic Mice Reveal a Role for CRE Binding Proteins in Multiple Stages of B Cell Development, Functional Maturation, Proliferation and Apoptosis. American Society of Hematology 46th Annual Meeting, San Diego, CA, December 6, 2004.*

62. Biswas S, Mone AP, Sen CK, Muthusamy N, Byrd JC. Arsenic Trioxide and Ascorbic Acid Enhances the Cytotoxicity of Hu1D10 towards CLL Cells. ASH Annual Meeting Abstracts. 2004;104:3479.

63. Gowda AC, Zhao XB, Cheney C, Mehter N, Lozanski G, Lin TS, Guster SK, Drachman JG, Muthusamy N, Byrd JC. Humanized Anti CD-40 Antibody SGN-40 Effectively Induces Cytotoxicity Against Chronic Lymphocytic Leukemia (CLL)

29


Cells through Antibody Mediated Cytotoxicity and Demonstrates Modest Biologic Evidence of CD40 Activation. ASH Annual Meeting Abstracts. 2005;106:2966.*

64. Johnson AJ, Edwards RE, Smith LS, Lucas DM, Croce, CM, Muthusamy N, Chen CS, Liu Z, Chan K, Grever MR and Byrd JC. Characterization of the TCL-1 Transgenic Mouse is an effective tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia. Blood (2005)106:110.*

65. Opavsky R., Tsai SY, Sharma N, Guimond G, Arora A, Opavska J, Trikha P, Maiti B,Wu L, Becknell B, Kaufmann M, Walton N, Stephens JA, Fernandez SA, Muthusamy N , Felsher DW, Caligiuri MA, Leone G. Novel E2F2B isoform functions as tumor suppressor in myc induced T cell lymphomagenesis. Cold Spring Harbor Symposium 2005.*

66. Zhao XB, Carolyn C, Gowda A, Ledbetter J, Ledbetter M, Baum P, Grosmaire L, Espling E, Young D, Lin T, Lee RJ, Caligiuri M, Muthusamy N, Byrd JC, Novel anti-CD37 small modular immunopharmaceutical (SMIP) demonstrated promising preclinical activity, Great Lakes PharmaScience Symposium 2005, Toronto, Jul, 2005.*

67. Zhao XB, Cheney C, Gowda A, Ledbetter J, Ledbetter MH, Baum P, Grosmaire L, Espling E, Young D, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC. CD37 Directed Single Chain Fv-Ig Demonstrates Promising Preclinical Activity against Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia. American Association for Cancer Research (2006) 47:276 (#1169).*

68. Santhanam S, Neviani P, Oaks J, Eiring AM, Notari M, Blaser B, Liu S, Trotta R, Muthusamy N, Marcucci G, Gambacorti-Passerini C, Roy DC, Verrills NM, Caligiuri MA, Bloomfield C, Chen C-S, Byrd JC, Perrotti D. FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL patients. American Society of Hematology 48th Annual Meeting, Orlando, FL, Dec, 2006.*

69. Lapalombella R, Zhao XB, Grosmaire L, Ledbetter JA, Muthusamy N, Byrd JC . Drug Induced Caspase Independent Cellular Cytotoxicity Is Associated with Activation of Phosphotyrosine-Mediated Signaling Events in Primary Chronic Lymphocytic Leukemia (CLL) B Cells. American Society of Hematology 48th Annual Meeting, Orlando, FL, Dec, 2006.*

70. Liu Q, Zhao XB, Frissora F., Ma Y, Santhanam R, Perrotti D, Chen CS, Dalton J, Byrd JC, Muthusamy N. FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma. American Society of Hematology 48th Annual Meeting, Orlando, FL, Dec, 2006.*

30


71. Zhao XB, Joshi T, Lapalombella R, Cheney C, Gowda A, Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL, Oral presentation in American Society of Hematology 48th Annual Meeting, Orlando, FL, Dec, 2006.*

72. Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R Muthusamy N, Marcucci G, Gamracorti C, Roy D-C, Claiguiri M., Bloomfield C, Chen C-S, Byrd, JC, Perrotti D. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. ASH Annual Meeting Abstracts. 2006;108:288.*

73. Muthusamy N , Grabenstatter J, Frissora F, Liu Q, Biswas S, Chen CS and Byrd JC. Thiazolidinedione derivative E5-[4-(6-allyoxy-2,5,7,8-tetramethyl-chroman-2-yl-methoxy)-benzylidene]-2,4-thiazolidinedione mediateS apoptosis in B cell lines and B cells from Chronic lymphocytic leukemia patients by cyclin D1 independent mechanism. American Association for Cancer Research (2006) 47:1161(#4942).*

74. Nagaleekar VK, Diehl S, Juncadella I, Charland C, Garrett-Sinha LA, Muthusamy N, Anguita J, Rincón M. Ets1-dependent IP3R3 expression in naïve CD4+ T cells is required for cytokine gene expression. American Association of Immunologists- Annual meeting 2007. J. Immunol., Apr 2007; 178: 87.22.

75. Gowda AC, Ramanunni A, Cheney C, Roda J, Kindsvogel W, Henderson D, Pallavur S, Carson W, Muthusamy N and Byrd JC. IL-21 enhances chemoimmunotherapy mediated death of chronic lymphocytic leukemia cells Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7094.*

76. Roda JM, Gowda A, Hussain R, Ramanunni A, Lehman A, Kindsvogel W, Carson WE, Muthusamy N, Byrd JC. IL-21 Promotes Apoptosis through Induction of the BH3 Only Protein Bim and Enhacnes Direct and Innate Immune-Promoted Death of Chronic Lymphocytic Leukemia Cells. ASH Annual Meeting Abstracts. 2007;110:3118.*

77. Roda JM, Lapalombella R, Baiocchi R, Zhukocksy E, Desjarlais J, Muthusamy N, Byrd JC. Pre-Clinical Activity of a Novel Fc{gamma}RIIIa Engineered CD19 Monoclonal Antibody in B Cell Chronic Lymphocytic Leukemia and Acute Lymphoblastic Leukemia. ASH Annual Meeting Abstracts. 2007;110:2351.*

78. Lapalombella R, Zhao XB, Baum PR, Ledbetter JA, Muthusamy N, Byrd JC. Role of CD37SMIP a Novel Engineered Small Modular Immunopharmaceutical in the Treatment of CLL. ASH Annual Meeting Abstracts. 2007;110:801.*

79. Garzon R, Liu S, Fabbri M, Liu Z, Pang J, Muthusamy N, Blum W, Chan K, Byrd JC, Croce CM, Marcucci G. MicroRNA (miRNA)-29b Targets DNMT3A and B and

31


Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML). ASH Annual Meeting Abstracts. 2007;110:718.*

80. Lapalombella R, Zhao XB, Ledbetter JA, Baum P, Muthusamy N, Byrd JC. Role of a novel CD37-specific engineered small modular immunopharmaceutica (SMIPTM) drug in the treatment of CLL. XII International Workshop on Chronic Lymphocytic Leukemia, Sep 14-16, 2007 London, UK.*

81. Muthusamy N , Gowda AC, Ramanunni A, Cheney C, Roda J, Kindsvogel W, Henderson D, Pallavur S, Carson W, and Byrd JC. IL-21 enhances chemoimmunotherapy mediated death of chronic lymphocytic leukemia cells. XII International Workshop on Chronic Lymphocytic Leukemia, Sep 14-16, 2007 London, UK.*

82. Alinari L, Hertlein E, Goldenberg DM, Lapalombella R, Yan F, Zhang X, Lucas DM, Muthusamy N, Byrd JC, Baiocchi RA. Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma. ASH Annual Meeting Abstracts. 2008;112:886*.

83. Baum PR, Cerveny, C, Gordon B, Nilsson C, Wiens J, Rafig S, Lapalombella R, Muthusamy N, Byrd JC, Wahl A. Evaluation of the Effect of TRU-016 an anti-CD37 Directed SMIP in Combination with Other therapeutic Drugs in Models of Non-Hodgkin’s Lymphoma. ASCO Annual Meeting Abstracts, May, 2009, Orlando, FL. J Clinical Oncology 27:7s (suppl; abstr. 8571).

84. Byrd JC, Lapalombella R, Ramanunni A. Andritsos LA, Flynn JM, Baum PR, Thompson P, Muthusamy N. Effect of CD37 Small Modular Immuno-pharmaceutical (SMIP) on Direct Apoptosis in Chronic Lymphocytic Leukemia Cells via Transcriptional Up-regulation of the BH3 Family Member BIM. ASCO Annual Meeting Abstracts, May 2009, Orlando, FL. J Clinical Oncology 27:7s (suppl; abstr. 3035).

85. Xie Z, Liu Z, Muthusamy N, Byrd JC, Yamada K, Chan K. A Validated Ultra-sensitive Hybridization-ELISA FOR Quantification of CpG685 on Plasma and Cell Lysate and its preclinical Pharmacokinetics in Mice. AAPS Abstracts, November 2009, Los Angeles, CA.

86. Alinari L, Christian B, Yu B, Shin J, Hertlein E, Lapalombella R, YanF , Lesinski GB, Zhang X, Lozanski G, Muthusamy N, Goldenberg DM, Byrd JC, Baiocchi RA. Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death that is Dependent on Actin Polymerization and Inhibition of NF-kB. 2009 ASH Annual Meeting, New Orleans, LA.*

87. Alinari L#, Liu Q#, Chen C-S, Yan F, Dalton JT, Lapalombella R, Zhang X, Lin T, Byrd JC, Baiocchi RA*, Muthusamy N * #These two first authors contributed equally to the work described herein. *These two senior authors contributed equally

32


to the work described herein. FTY720 Demonstrates Promising in-vitro and in-vivo Pre-clinical Activity by Down-modulation of Cyclin D1 and pAkt in Mantle Cell Lymphoma . 2009 ASH Annual Meeting, New Orleans, LA.*

88. Rafiq S, Cheney C, Thompson PA, Siadak T, Algate P, Cerveny C, Byrd JC, Muthusamy N. Glycovariant CD37 Small Modular Immuno-pharmaceutical (TruADhanCe™ SMIP) promotes enhanced Natural killer cell mediated cytotoxicity against primary chronic lymphocytic leukemia cells. 2009 ASH Annual Meeting, New Orleans, LA.*

89. Bai Y, Ma Y, Kulp SK, Wang S-H, C-F, Frissora F, Mo X, Jarjoura D, Byrd JC, Chen C-S, Muthusamy N. OSU-DY7, a Novel D-tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma Through p38 Mitogen-Activated Protein Kinase Pathway. 2009 ASH Annual Meeting, New Orleans, LA.*

90. Xie Z, Liu Z, Chen P, Muthusamy N, Byrd JC, Yamada K, Chan KK A Validated Ultra-sensitive Hybridization-ELISA for Quantification of CpG685 in Plasma and Cell Lysate and its Preclinical Pharmacokinetics in Mice. Annual Meeting of Am Assoc Pharmaceutical Scientist in Los Angeles Nov 7-14, 2009.

91. Awan F, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson D, Cheney C, Mo X, Lehman A, Jones JA, Flynn JM, Jarjoura D, Baiocchi RA, Desjarlais J, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC. CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody. 2009 ASH Annual Meeting, New Orleans, LA.*

92.Browning RL, Wang S-H, Ramanunni A, Muthusamy N, Byrd JC. Transcriptional up-Regulation of IL-21 Receptor- On CLL Cells by CpG685 through An NF- B Mediated Pathway Provides a Rationale for Combination Strategies with IL-21. 2009 ASH Annual Meeting, New Orleans, LA.*

93. Hertlein EK, Triantafillou G, Hessler J, Zhang X, Jarjoura D, Lucas DM, Lee RJ, Muthusamy N, Goldenberg DM, Byrd JC. Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells. 2009 ASH Annual Meeting, New Orleans, LA.*

94. Andritsos L, Furman RR, Flinn IW, Foreno-Torres A, Flynn JM, Muthusamy N, Rafiq S, Stromatt S, Byrd JC. A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIPTM) Protein in Relapsed and Refractory CLL Early Promising Clinical Activity. 2009 ASH Annual Meeting, New Orleans, LA.*

95. Maddocks K, Lapalombella R, Blum KA, Blum W, Fischer BB, Muthusamy N, Moran ME, Holtzapfel D, Byrd JC, Johnson AJ, Andritsos L. Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.

33


2009 ASH Annual Meeting, New Orleans, LA.*

96. Butchar JP, Mehta P, Justiniano SE, Guenterberg KD, Kanneganti T-D, Amer A, Muthusamy N, Jarjoura D, Marsh CB, Carson WE, III, Byrd JC, and Tridandapani S. TLR7/8 Differentially Regulates Fc Receptor Expression and Function. 2009 ASH Annual Meeting, New Orleans, LA.*

97. Yu B, Mao Y, Bai L-Y, Herman SEM, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee R, Lee LJ, Byrd JC, Muthusamy N. Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of

Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia. 2010 ASH Annual Meeting, Orlando, FL .

98. Herman SEM, Lapalombella R, Jones JA, Andritsos L, Gordon AL, Ramanunni A, Lannutti B, Muthusamy N, Byrd JC, Johnson AJ. Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase- Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia. 2010 ASH Annual Meeting, Orlando, FL.

99. Rafiq S, Cheney CM, Lozanski G, Lapalombella R, Mo X, Siadak A, Jarjoura D, Byrd JC, Muthusamy N. GlycoVariant Anti-CD37 Small Modular Immuno- Pharmaceutical Exhibits Superior Natural Killer Cell Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells at Low Concentrations and Low Antigen Density. 2010 ASH Annual Meeting, Orlando, FL.

100.Muthusamy N, Yu B, Mao Y, Bai L-Y, Herman SEM, Ramanunni A, Mo X, Yan J, Cheney C, Chan KK, Jarjoura D, Marcuci G, Lee RJ, Byrd JC, Lee LJ. Targeted Nanoparticle Delivery Overcomes Off-Target Immunostimulatory Effects of Eligonucleotides and Improves Therapeutic Efficiacy. 2011 IWCLL Meeting, Houston, TX.

101. Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang C-H. Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts). 2011; 118:599.

102. Alinari L, Mahoney E, Patton JT, Zhang X, Huynh L, Earl CT, Mani T, Mao Y, Yu B, Towns WH, Chen C-S, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Ibba M, Baiocchi RA. FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death. Blood (ASH Annual Meeting Abstracts). 2011; 118:600

103. Lapalombella R, Ramanunni A, Yeh Y-Y, Wang L, Jha S, Staubli J, Herman SEM, Andritsos LA, Jones JA, Flynn JM, Mo X, Johnson AJ, Thompson P, Algate PA, Stromatt S, Freitas MA, Muthusamy N, Byrd JC. Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Blood (ASH Annual Meeting Abstracts). 2011; 118:622.

34


104. Rafiq S, Butchar JP, Cheney C, Mo X, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC. Comparative Assessment of Different Clinically Utilized CD20 Directed Antibodies in Chronic Lymphocytic Leukemia (CLL) Cells Reveals Divergent NK-Cell, Monocyte and Macrophage Properties. Blood (ASH Annual Meeting Abstracts). 2011; 118:3717.

105. Mani R, Frissora FW, Chen C-S, Byrd JC, Muthusamy N. OSU-2S, A Novel FTY720 derivative, Mediates Cytotoxicity In Chronic Lymphocytic Leukemia Through PKC Dependent Modulation of SHP1 Tyrosine PhosphataseBlood (ASH Annual Meeting Abstracts). 2011; 118:2499.

106. Huang X, Schwind S, Yu B, Pang J, Santhanam R, Chan KK, Garzon R, Blum W, Bloomfield CD, Liu S, Perrotti D, Lee RJ, Byrd JC, Muthusamy N, Lee LJ, Marcucci G. Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts). 2011; 118:81.

107. Boukany, P, Want X, Zhao X, Wu Y,Juang X, Yu B, Schwind S, Byrd JC, Muthusamy N, Marcucci G, Lee LJ. Delivery of Neucleic Acids by Nanochannel Electroporation for Cancer Research. OSUCCC – James 14th Annual Scientific Meeting, Columbus, OH, March, 2012.

108. Huang X, Schwind S, Eisfeld A-K, Hickey C, Ramasamy S, Chen K, Perrotti D, Muthusamy N, Byrd JC, Blum W, Bloomfield C, Garzon R, Lee R, Lee LJ, Marcucci G. Synthetic microRNA (miR)-181a Nanoparticles (NP) Target RAS and Sensitize Cells to Daunorubicin (DNR) in Acute Myeloid Leukemia (AML). OSUCCC – James 14th Annual Scientific Meeting Columbus, OH, March, 2012.

109. Beckwith, K, Frissora F, Byrd JC, Muthusamy N. Generation and Characterization of a Human CD37 Transgenic Mouse for the Evaluation of Anti-CD37 Therapeutics. OSUCCC – James 14th Annual Scientific Meeting, Columbus, OH, March, 2012.

110. Mani R, Frissora F, Mo X, Jarjoura D, Chen C-S, Byrd JC, Muthusamy N. OSU-2S, A Novel FTY720 Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia through PKS Dependent Moduclation of SHP1 Tyrosine Phosphatase. OSUCCC – James 14th Annual Scientific Meeting, Columbus, OH, March, 2012.

111. Rafiq S, Butchar J, Cheney C, Mo X, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC. Comparative Assessment of Different Clinically Utilized CD20 directed Antibodies in Chroonic Lymphocytic Leukemia (CLL) Cells reveals Divergent NK-cell, Monocyte and Macrophage Properties. OSUCCC – James 14th Annual Scientific Meeting, Columbus, OH, March, 2012.

112. Dubovsky J, Andritsos L, Blum W, Johnson AJ, Muthusamy N, Byrd JC. Immunoglobulin Reactivity Analysis of Chronic Lymphocytic Leukemia Patients

35


unveils Lymphocyte Cytosolic Protein 1 (LCP1) as a Novel CLL Exosome Antigen. OSUCCC – James 14th Annual Scientific Meeting, Columbus, OH, March, 2012.

113. Huang X, Schwind S, Eisfeld A-K, Jin Y, Yu B, Hickey C, Pang J, Ramasamy S, Chan KK, Perrotti D, Muthusamy N, Byrd JC, Blum W, Bloomfield C, Liu S, Garzon R, Lee R, Lee L, Marcucci G. Abstract 1111: Synthetic microRNA (miR)-181a nanoparticles (NP) target RAS and sensitize cells to daunorubicin (DNR) in acute myeloid leukemia (AML) Cancer Res. (AACR Annual Meeting Abstract) 2012; 72:1111.

114. Dubovsky JA, Andritsos LA, Blum W, Johnson AJ, Muthusamy N, Byrd JC. Abstract 509: Immunoglobulin reactivity analysis of chronic lymphocytic leukemia patients unveils Lymphocyte Cytosolic Protein 1 (LCP1) as a novel CLL exosome antigen. Cancer Res. (AACR Annual Meeting Abstract)2012; 72:509.

115. Motiwala T, Zanesi N, Roy S, Mustafa M, Kutay H, You J, Frissora F, Lu Y, Muthusamy N, Freitas M, Croce CM, Jacob ST. Abstract 1351: Analysis of the in vivo tumor suppressive potential of PTPROt (truncated protein tyrosine phosphatase receptor-type O) in CLL using a transgenic mouse model. Cancer Res. (AACR Annual Meeting Abstract) 2012; 72:1351.

116.Dubovsky JA, Beckwith KS, Woyach JA, Jaglowski SM, Hessler J, Chang BY, Larkin K, Stefanovski MR, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman A, Furman RR, Sharman J, Mishra A, Caligiuri MA, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells. Blood (ASH Annual Meeting Abstracts). 2012; 120:775. (Oral presentation)

117. Beckwith KA, Frissora FW, Stefanovski MR, Deckert J, Croce CM, Mo X, Jarjoura D, Byrd JC, Muthusamy N. A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics. Blood (ASH Annual Meeting Abstracts). 2012; 120:188. (Oral presentation)

118. Huang, Schwind S, Eisfeld A-K, Yu B, Ramasamy S, Hoellerbauer P, Jin Y, Hickey C, Pang J, Chan KK, Perrotti D, Muthusamy N, Byrd JC, Blum W, Bloomfield CD, Liu S, Garzon R, Lee RJ, Lee LJ, Marcucci G. Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts). 2012; 120:2422.

119. Chappell DL, Dubovsky JA, Andritsos LA, Flynn JM, Jones JA, Byrd JC, Muthusamy N. Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling. Blood (ASH Annual Meeting Abstracts). 2012; 120:3866.

36


120. Butchar JP, Shah P, Patel H, Fatehchand K, Rafiq S, Cheney C, Vasilakos JP, Muthusamy N, Byrd JC, Tridandapani S. TLR7/8 Agonists Overcome the Suppression of Fc R Activity in Monocytes From Chronic Lymphocytic Leukemia Patients. Blood (ASH Annual Meeting Abstracts). 2012; 120:4595.

121. Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson, DM Jr., Muthusamy N, Devine SM, Andritsos LA, Lozanski G. Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease. Blood (ASH Annual Meeting Abstracts). 2012; 120:1949.

122. Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos LA, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson, DM Jr., Muthusamy N, Devine SM, Lozanski G. Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD). Blood (ASH Annual Meeting Abstracts). 2012; 120:4192.

123. Natarajan G, Dubovsky J, Satoskar A, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib (PCI-32765) administration modulates a Th1 dominated immune response during cutaneous leishmaniasis infection (P3070). J. Immunol. (AAI Annual Meeting), 2013; 190:187.10.

124. Muthusamy N, Mao Y, Frissora F, Mani R, Wang J, Wu Y, Yu B, Baskar S, Rader C, Phelphs M, Chen S-C, Lee R, Lee JL, Byrd JC. ROR1 directed delivery of FTY720 derivative OSU-2S mediates potent cytotoxic activity against chronic lymphocytic leukemia but not normal B cells in-vitro and in ROR1 expressing transgenic CLL mouse model in-vivo (P3275). J. Immunol. (AAI Annual Meeting). 2013; 190:192.23.

125. Mani R, Frissora F, Mao Y, Chiang C-l, Mo X, Jarjoura D, Baskar S, Rader C, Lee R, Lee LJ, Chen S-C, Byrd JC, Muthusamy N. OSU-2S: a novel non-immunosuppressive FTY720 derivative mediates potent cytotoxic activity through PKC dependent phosphorylation of tumor suppressor SHP1 and down modulation of Tcl1 oncogene in chronic lymphocytic leukemia (P2120). J. Immunol. (AAI Annual Meeting) 2013; 190:132.50.

126. Beckwith KA, Frissora FW, Stefanovski MR, Cheney C. Mo X, Deckert J. Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N. Generation and validation of a novel human CD37-positive chronic lymphocytic leukemia mouse mode for pre-clinical evaluation of human CD-37 directed therapeutics. iWCLL (International Workshop on Chronic Lymphocytic Leukemia) Cologne, Germany, 2013

37


127. Stephens DM, Stark A, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. Changing the Treatment Paradigm for Previously Treated Chronic Lymphocytic Leukemia Patients with Del(17p) Karyotype. Blood 2013 (ASH Annual Meeting Abstracts) 122:2872.

128. Heerema NA, Muthusamy N, Ruppert AS, Andritsos LA, Grever MR, Jones JA, Maddocks K, Byrd JC. Prognostic Significance Of Cytogenetic Complexity and Del(17p) At Diagnosis Of Chronic Lymphocytic Leukemia (CLL). Blood 2013 (ASH Annual Meeting Abstracts) 122:1321.

129. Wang H, Ramasamy S, Xie Z, Huang X, Chiu M, Phelps MA, Walker AR, Caligiuri MA, Garzon R, Lee J, Muthusamy N, Chan KK, Marcucci G. Decitabine Or 5-Azacitidine Pre-Treatment Does Not Compromise The Novel Fc-Engineered Antibody Mab 33.1-Mediated ADCC Against Primary AML Blasts - A Rationale For Combination Therapy. Blood 2013 (ASH Annual Meeting Abstracts) 122:3959.

130.Kohrt HE, Idit S-B, Rafiq S, Herman SEM, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC. Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity. Blood 2013 (ASH Annual Meeting Abstracts) 122:373.

131.Stephens DM, Stark A, Wierda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam GS, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC. Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients. Blood 2013 (ASH Annual Meeting Abstracts) 122:4128.

132.Mani R, Mao Y, Frissora FW, Chiang C-L, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Baskar S, Rader C, Phelps MA, Lee RJ, Chen C-S, Lee J, Byrd JC, Muthusamy N. Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia. Blood 2013 (ASH Annual Meeting Abstracts) 122:4168.

133.McWilliams EM, Cheney C, Jones JA, Flynn JM, Maddocks K, Andritsos LA, Huet H, Gram H, Baeck J, Muthusamy N, Byrd JC. B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo. Blood 2013 (ASH Annual Meeting Abstracts) 122:4185.

134. Sumithira Vasu, Anissa Bingman, Susan Geyer, Patrick Elder, Rhonda Kitzler, Hillary Bradbury, Lynn Odonnell, William Blum, Samantha M. Jaglowski, Leslie A. Andritsos, Rebecca B. Klisovic, Sam Penza, Yvonne A Efebera, Craig C. Hofmeister, Don M. Benson, Muthusamy N, Gerard Lozanski, Steven M. Devine.

38


Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation. Blood 2014 (ASH Annual Meeting Abstracts) 124:2494

135. Deborah M Stephens, Kyle A Beckwith, Carolyn Cheney, Xiaokui Mo, Joseph M Flynn, Jeffrey A. Jones, Kami J. Maddocks, Karl-Heinz Heider, Muthusamy N, John C. Byrd. BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia. Blood 2014 (ASH Annual Meeting Abstracts) 124:4681

136. Christopher Brooks, Janice Chen, David M. Lucas, Muthusamy N, Ivan Bergstein, Eric Rowinsky. SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia. Blood 2014 (ASH Annual Meeting Abstracts, online publication) 124:5663

137. Rajeswaran Mani, Chi-Ling Chiang, Frank W. Frissora, Ribai Yan, Xiaokui Mo, Sivasubramanian Baskar, Christoph Rader, Mitch Phelps, Ching-Shih Chen, Robert Lee, John Byrd, Robert Baiocchi, L. James Lee, Muthusamy N. ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle cell lymphoma in-vitro and in-vivo. 2015 Proceedings of the American Association for Cancer Research.4406.

138. Rajeswaran Mani, Bhavani Gopalakrishnan, Xiaokui Mo, Chris Brooks, William Blum, Gerard Lozanski, Sumithira Vasu, Muthusamy N. SL-401 activity against AML blasts correlates with CD123 levels and does not down-regulate CD123 expression. 2015 Proceedings of the American Association for Cancer Research. 1691.

INVITED LECTURES (SELECTED – SINCE 2006):

2006 National Workshop on “Recent Developments in Cancer Management and reseach- Avinahsilingam” Home Science University, Coimbatore, India (December 15, 2006)

2007 The Babraham Institute, “Differential role for CREB transcription factor in multiple stages of B-cell development and functional maturation.” Babraham Research Campus, Babraham, Cambridge United Kingdom. Sept 17, 2007.

2009 12th Annual Meeting, Translational Research Cancer Center Consortium (TRC3), “IL-21 – The new cytokine on the block for CLL”, Philadelphia, PA,

(March 5-6, 2009).

2011 15th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma. “Therapeutic Antibodies: A Decade of Design” Whistler, British Columbia, Canada (February 17-20, 2011)

39


2011 4th International Conference on Translational Cancer Research: Recent Developments in Cancer Prevention, “Prospects for Targeted Nanoparticle Delivery in B Cell malignancies” Udaipur, Rajasthan, India (December 16-19, 2011)

2011 Session Co-Chair 4th International Conference on Translational Cancer Research: Recent Developments in Cancer Prevention, Minisymposium on “Overcoming survival mechanisms in Cancer” Udaipur, Rajasthan, India (December 16-19, 2011)

2011 Invited Visiting Professor – Senior leadership committee on building a bridge with US universities, Avinasilingam University ( An Institute for Home Science and Higher Education for Women), Coimbatore, India (December 20-26, 2011)

2012 CLL Research Consortium (CRC) Annual Meeting “Study of CD37 and Mouse Models”, LaJolla, CA (February 10-12, 2012).

2012 The Henry Kunkle Society and IMPAM meeting on Immunological Memory in Health and Disease “Tetraspanin CD37 mediates Transduction of survival and Apoptotic signals in B cells. Berlin, Germany (Jun 3-6, 2012).

2012 Boehringer Ingelheim, Vienna, Austria “A dual signaling role for CD37 tetraspanin – A tale of two tails” (June 1, 2012)

2012 5th European Conference on Tetraspanins, Amsterdam, Netherlands (“Dual signaling role for Tetraspanin CD37 in B cells – a tale of two tails”. (Sept. 26-28, 2012).

2013 University of Nebraska Medical Center Departmental Seminar “CD37 Tetraspanin – a therapeutic target in B-cell malignancies”. (February 13, 2013)

2013 The Henry Kunkle Society Annual Meeting “CD37 Tetraspanin as a Therapeutic Target for B-Cell Malignancies”. New York, NY. (April 17-20, 2013)

2013 The University of Kentucky – “CD37 Tetraspanin targeted therapies for B-cell malignancies”. Lexington, KY (August 7, 2013)

2013 CLL Research Consortium- ASH meeting “Human ROR-1 Targeted Delivery of a novel FTY720 derivative OSU-2S in CLL (December 5, 2013)

2014 The Department of Science and Technology-Curie Workshop- Avinashilingam University for Women, Coimbatore India “Challenges with conventional drug design for leukemia Biotechnology and molecular biological applications come to rescue” (January, 24, 2014)

40


2014 Avinashilingam University for Women- Research Convention-“Research- An Integrated Enterprise”-Invited speaker- (February 5, 2014)

2014 Kuppusamy Naidu Memorial Cancer Hospital, Coimbatore, India _invited talk” Novel therapies for leukemia and Lymphoma” (February 7, 2015)

2014 CLL Research Consortium (CRC) Annual Meeting “ CD37 Tetraspanin- a therapeutic target in CLL” , San Diego, CA (April 23, 2014)

2014 Radboud University Medical Center, The Netherlands. – NCMLS Nijmegen Lecture Series and Erasmus MC University Departmental Seminar. “Beyond Scaffolding- Tetraspanins as therapeutic targets in B cell malignancies.” Rotterdam, Netherlands (October 30, 2014)

2014 University of Utrecht, The Netherlands,- Genmab B.V. – Genmab Seminar Series on Advances in Immunotherapy, “Novel animal models in emerging antibody therapy” (October 31, 2014)

2014 Boehringer Ingelheim RCV GmbH & Co KG Austria – “Fc-engineered antibody therapy–combination opportunities in acute and chronic leukemia.” (November 3, 2014)

PROFESSIONAL SOCIETIES:

1992- Member - American Association of Immunologists1989- Member - American Association for Advancement of Science2009- Member - American Association of Cancer Research2009- Member - American Society of Hematology 2012 - Member - Henry Kunkle Society

SERVICES (ADMIN., COMMITTEES & OTHER)

a. Department committees:

1) 1998-2004- Member- Institutional Animal Care and Use Committee Columbus Children's Hospital2) 1999-2004- Member- Radiation Safety Committee, Columbus Children’s Hospital3) 1999-03- Member- Graduate Studies Committee, Dept. of Molecular Virology, Immunology and Medical Genetics4) 1997-2004- Director- Embryonic Stem Cell core facility,

Children’s Research Institute 5) 2001-Member- Faculty Search Committee, Dept. of Veterinary BioSciences6) Strategic Planning Committee, 2002, Dept. of Veterinary

41


BioSciences7) Division of Hematology Mentorship Committee8) Division of Hematology Finance Committee

b. College or University committees:

1) Member-OSU-GATEWAY Program- India Faculty advisory Committee (2011 - present)2) Member-IBGP Graduate Studies Committee (2011-present)3) Member-The OSU Veterinary Sub-committee on Animal policies, ULAR (2007 – present)4) Member-Graduate Education Committee- College of Medicine and Public Health, The Ohio State University (1999-2004).5) Secretary-Graduate Education Committee- College of Medicine and Public Health, The Ohio State University (1999-2004).6) Pelotonia Fellowship Program Committee7) Center for FAME, The Ohio State University (2014 – present)

c) Editorial Services

a. Journal Editorial Reviewer:

1) Journal of Immunology2) Blood3) Journal of Leukocyte Biology4) Cancer Research5) Hematologica6) Therapeutic Delivery7) Leukemia8) Molecular Medicine9) PLoS ONE10) Leukemia and Lymphoma11) Dataset Papers in Medicine 12) Conference Papers in Medicine13) Cytokine14) Biomaterials15) Nanomedicine16) Journal of Nanoscience Letters

b: Editorial Board

1) Journal of Postgenomics: Drug & Biomarker Development

c: Editor-in-Chief

1) Metabolomics: Open Access (2011-2013)

42


d) Service to OSU Student and Other Local Organizations

1) The Ohio State University Office of Minority Affairs Retention services mentoring program

2) High School District Science Fair- Judge3) Thomas Worthington High School-Science fair Mentor4) Judge- Landacre Society5) Judge- Bennett Society6) Judge- Graduate Student Council.7) Judge-2006-present- HLRI Annual Research Day- Division of

pulmonary, allergy Critical care and sleep medicine.8) Leukemia and Lymphoma Society9) Judge-Edward F-Hayes- Graduate Research Forum10) Faculty Co-Advisor to AID- Columbus- (OSU Student organization

supporting grass root level activities on health Education and women empowerment in India (Outstanding advisor to OSU student organizations-award 2012-13)

11) The Ohio State University, Judge, Denman Research Forum12) Tech Columbus, Medical Advisory and Evaluation Board Member13) Faculty Advisor, South Asian Student Association (OSU Student

organization advocating for the South Asian community)14) The Ohio State University, Poster Judge, OSUWMC Trainee

Research Day (April, 2014)15) T32 Hematology/Oncology Fellow Lecture (Sept. 2014)

e) Contributions to National/International Professional Organizations

1) American Society of Hematology Committee on Promoting Diversity, Career Development Mentor (2013)

f) Grant Application Review Panel

1) Susan G. Komen Breast Cancer Foundation (2001-2003)2) Cancer Research UK, London (2003)3) The Ohio State University, Comprehensive Cancer Center

IntramuralResearch Program (2013)4) National Science Center, Krakow, Poland (2013)5) Leukemia & Lymphoma Research, UK (2012)6) Leukemia & Lymphoma Society, Translational Research Program

(2012 – present)6) NIH/NCI SEP Review Committee – R21/R03 Proposals on Novel

Therapeutics/Pre-clinical and clinical studies (December, 2013)7) Pelotonia Postdoctoral Application Review, The Ohio State

University (March 2014)

43


8) NIH/NCI SEP Review Committee – K22 Applications (April, 2014)

9) Dutch Cancer Society Grant Review Panel (April, 2014)10) The Ohio State University, Comprehensive Cancer Center

Intramural Research Program, Clinical/Translational Science (Sept. 2014)

11) The Ohio State University, Shared Core Facilities (Nov. 2014)

g) Scholarship Application Review Panel

1) The Ohio State University, College of Medicine, Medical Student Research Scholarship Applications (2013)

44

Date post:	25-Mar-2018
Category:	Documents
Upload:	dinhtram
View:	252 times
Download:	3 times

CURRICULUM VITAE - Ohio State University · Web viewCURRICULUM VITAE PERSONAL DATA: Name:...

Documents